DUBLIN, Ireland, June 4, 2026
Jazz Pharmaceuticals has announced the presentation of an extensive portfolio of new clinical and real-world research at SLEEP 2026, the 40th Annual Meeting of the Associated Professional Sleep Societies (APSS), highlighting the broad therapeutic impact of Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution in patients living with narcolepsy and idiopathic hypersomnia. The company will present 21 scientific abstracts, including 11 late-breaking presentations, demonstrating its ongoing commitment to addressing the significant unmet needs associated with rare and difficult-to-treat sleep disorders. The research program includes analyses from the DUET, LYRICAL, and XYLO studies, providing new insights into symptom management, sleep inertia, daytime functioning, quality of life, treatment satisfaction, cardiovascular health, and individualized dosing strategies. The breadth of evidence reflects Jazz Pharmaceuticals’ patient-centered approach to advancing care for individuals whose daily lives are profoundly affected by chronic sleep disorders.
New Data Highlight Benefits Beyond Excessive Daytime Sleepiness
Among the most notable presentations is a post-hoc analysis from the DUET study, which examines both objective and subjective improvements in sleep inertia among patients with narcolepsy treated with Xywav. Sleep inertia, often described as severe grogginess, confusion, and impaired functioning upon waking, remains one of the most challenging symptoms faced by patients with narcolepsy and idiopathic hypersomnia. Additional DUET analyses will explore outcomes in patients with idiopathic hypersomnia, evaluating improvements in sleep inertia and treatment effectiveness across different sleep-duration profiles.
Researchers will also present findings examining hypersomnolence outcomes among narcolepsy patients receiving higher Xywav doses, providing further understanding of treatment optimization. Collectively, these studies suggest that Xywav may offer benefits extending beyond traditional measures of excessive daytime sleepiness by addressing multiple symptoms that significantly impair daily functioning, productivity, and overall wellbeing. The findings reinforce growing recognition that successful management of sleep disorders requires a comprehensive approach targeting the full spectrum of disease burden.
Real-World Evidence Demonstrates Quality-of-Life Improvements
Advertisement
A major component of Jazz’s scientific program at SLEEP 2026 focuses on findings from the LYRICAL study, a longitudinal real-world investigation evaluating treatment experiences among adults living with narcolepsy and idiopathic hypersomnia. Six separate presentations from LYRICAL examine how Xywav therapy influences patient-reported outcomes, dosing patterns, symptom control, and quality of life. Results indicate that improvements in nighttime sleep quality and daytime symptom management are associated with meaningful gains in overall wellbeing. Additional analyses explore treatment satisfaction, individualized dosing approaches, and patient perspectives regarding long-term therapy.
Researchers will also present conceptual disease models for narcolepsy type 1 and type 2 developed from direct patient experiences, helping to identify the symptoms and life impacts considered most burdensome. These patient-centered insights are expected to support healthcare providers in making more informed treatment decisions while improving understanding of how sleep disorders affect daily life beyond traditional clinical endpoints.
Expanding Understanding of Long-Term Health and Personalized Treatment
Beyond symptom management, several presentations will explore the broader health implications of low-sodium oxybate therapy. New research evaluates changes in cardiovascular and cardiometabolic biomarkers following Xywav initiation in patients with narcolepsy and idiopathic hypersomnia, reflecting increasing interest in the long-term health benefits of reducing chronic sodium exposure. Additional studies investigate nocturnal sleep characteristics as potential mechanisms underlying improvements in daytime symptoms, offering deeper insights into disease biology and treatment response. Jazz will also present post-marketing analyses highlighting real-world dosing patterns and individualized treatment approaches, emphasizing the importance of personalized care strategies in managing complex sleep disorders.
As the only FDA-approved low-sodium oxybate therapy and the first approved treatment for idiopathic hypersomnia in adults, Xywav continues to play a central role in advancing sleep medicine research. The comprehensive body of evidence being presented at SLEEP 2026 further strengthens Jazz Pharmaceuticals’ position as a leader in neuroscience and rare sleep disorder innovation, while supporting ongoing efforts to improve outcomes for patients living with narcolepsy and idiopathic hypersomnia.
Source: Jazz Pharmaceuticals press release
